Original research articles

Court KA, Hatakeyama H, Wu SY, et al. HSP70 Inhibition Synergistically Enhances the Effects of Magnetic Fluid Hyperthermia in Ovarian Cancer. Molecular Cancer Therapeutics 2017, 16(5):966-976.

Wu, S.Y., Rupaimoole, R., Shen, F., et al. A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nature Communications 2016, 7:111169.

Hatakeyama, H., Wu, S.Y., Lyons, Y.A., et al. Role of CTGF in sensitivity to hyperthermia in ovarian and uterine cancers. Cell Reports 2016, 17(6):1621-31.

Miyake TM, Pradeep S, Wu SY, et al. XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A. Clinical Cancer Research 2015, 21(14):3286-97.

Wu, S.Y., Yang, X.B., Gharpure, K., et al. 2’-OMe-phosphorodithioate modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nature Communications 2014, 5, 3459.

Rupaimoole, R., Wu, S.Y., Pradeep, S., et al. Hypoxia mediated downregulation of miRNA biogenesis leads to increased tumor progression. Nature Communications 2014, 5:5202.

Pradeep, S., Kim, S.W., Wu, S.Y., et al. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell 2014, 26(1):77-91.

Pecot, C.V., Wu, S.Y., Bellister, S., et al. Therapeutic Silencing of KRAS using Systemically Delivered siRNAs. Molecular Cancer Therapeutics 2014, 13(12):2876-85.

Wu, S.Y., Chang, H.I., Burgess, M., et al. Vaginal delivery of siRNA using a novel PEGylated lipoplex-entrapped alginate scaffold system. Journal of Controlled Release 2011, 155(3):418-26.

Wu, S.Y., Singhania, A., Burgess, M., et al. Systemic delivery of E6/7 siRNA using novel lipidic particles and its application with cisplatin in cervical cancer mouse models.  Gene Therapy 2011, 18(1): 14-22.

Singhania, A.*, Wu, S.Y.*, McMillan, N.A.J. Effective delivery of PEGylated siRNA-containing lipoplexes to extraperitoneal tumours following intraperitoneal administration. Journal of Drug Delivery 2011, e192562.

*These authors contributed equally to the work.

Wu, S.Y., Putral, L.N., Liang M., et al. Development of a novel method for formulating stable siRNA-loaded lipid particles for in vivo use. Pharmaceutical Research 2009, 26(3):512-22.

Wu, S., Campbell, C., Koda, Y., et al. Investigation of the route of absorption of lipid and sugar modified Leu-enkephalin analogues and their enzymatic stability using the Caco-2 cell monolayer system. Medicinal Chemistry 2006, 2(2):203-11.

Review articles

Yang M, Wu, SY. The advances and challenges in utilizing exosomes for delivering cancer therapeutics. Front Pharmacol. 2018, 9:735.

Lyons, Y., Wu, S.Y., Overwijk, W.W., et al. Immune cell profiling in cancer: molecular approaches to cell-specific identification. NPJ Precision Oncology 2017, 1:Article 26.

Gharpure, K., Wu, S.Y., Li, C., et al. Nanotechnology: Future of oncotherapy. Clinical Cancer Research 2015, 21(14):3121-30.

Wu, S.Y.; Lopez-Berestein, G.; Calin, G.A.; et al. RNAi therapeutics: Drugging the undruggable. Science Translational Medicine 2014, 6:240ps7.

Hua, S.; Wu, S.Y. The use of lipid-based nanocarriers for targeted pain therapies. Frontiers in Neuropharmacology 2013, 4: 143.

Wu, S.Y. and McMillan N.A.J. Lipidic systems for in vivo siRNA delivery. American Association of Pharmaceutical Scientists Journal 2009, 11(4):639-52.

Editorials/Commentary/Book Chapters

Hatakeyama, H., Wu, S.Y., Mangala, L.S., et al. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models. Methods Mol Biol 2016,1402:189-97.

McCaskill, J.L., Wu, S., Khairuddin, N., et al. Lowering the siRNA delivery barrier: Alginate Scaffolds and Immune stimulation. In: Peer D, editor. Nanotechnology for delivery of Therapeutic Nucleic Acids. Pan Stanford Publishing Pte. Ltd. pp. 193-216 (2013).

Wu, S.Y. Cancer therapy hits its target. Australasian Science, 2010 April, p28-30.